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ABSTRACT 
 
IMPLEMENTATION OF RISK MANAGEMENT IN THE MEDICAL DEVICE 
INDUSTRY  
by Rachelo Dumbrique 
 This study looks at the implementation and effectiveness of risk management 
(RM) activities in the medical device industry.  An online survey was distributed to 
medical device professionals who were asked to identify RM-related activities performed 
during the device life cycle.  RM activities and techniques included Establishing Risk 
Acceptance Criteria, Hazard Identification, Human Factors/Usability, Fault Tree Analysis 
(FTA), Design Failure Mode and Effects Analysis (DFMEA), Process Failure Mode and 
Effects Analysis (PFMEA), Hazard and Operability Study (HAZOP), Hazard Analysis 
and Critical Control Point (HACCP), Risk Benefit Analysis, and Risk Assessment of 
Customer Complaint. Devices were identified by type (therapeutic, surgical/clinical tools, 
diagnostic, instrument disposable, implantable, etc.), development history (new, second, 
third or later generation device), and time since market release.  Respondents were also 
asked to indicate the degree of change made to the device as a result of RM activities and 
to rate the effectiveness of associated RM activities for the device.  Survey results 
indicated that RM’s impact and level of effectiveness on a medical device are dependent 
primarily on the device type and life-cycle stage (i.e., pre-market versus post-market).  
There is also some impact of development history and the time since the device was 
released to market.  
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Introduction 
 The extensive innovations in medical device technology have supported the 
increasing demands of the health care industry over the past twenty years (Foote, 1988).  
Even in a highly technology-driven environment, it is still crucial that products are 
designed and developed to meet requirements of relevant International Organization for 
Standardization (ISO) standards and Food and Drug Administration (FDA) regulations 
that assure quality and safety.  
 Product liability and regulation have increasingly become major issues for the 
medical devices industry (Foote, 1988).  For this reason, medical device manufacturers 
and the FDA face the challenging role of ensuring a stringent process is in place for 
medical device risk assessment.  But with all the standards and regulations imposed for 
the assurance of a medical device’s effectiveness and safety, the amount of risk involved 
is still in question on devices that are approved for market release (Dyadem International, 
2008).  A 100% risk-free device is never attainable (T. Chan, personal communication) 
but a systematic assessment of potential risks associated with a medical device can 
significantly reduce potential harm to the user, manufacturer, and the medical device 
industry in general. 
 This study focused on the implementation of selected risk-analysis activities and 
techniques over the life cycle of a medical device.  This study studied its impact for an 
effective risk management, that, when effectively carried out, will help to significantly 
reduce product returns and litigations.  The risk analysis techniques include Risk 
Acceptance Criteria, Hazard Identification/Preliminary Hazard Analysis (PHA), Human 
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Factors/Usability Analysis/Use Failure Mode and Effects Analysis (FMEA), Design 
FMEA, Process FMEA, Hazard Operability Study (HAZOP), Hazard Analysis and 
Critical Control Point (HACCP), Risk Benefit Analysis, and Risk Assessment of 
Customer Complaint.  The use of these techniques was evaluated in the different phases 
of the design life cycle, which includes conceptualization, initial development, design 
verification and engineering validation, design transfer, clinical validation, pilot 
production, manufacturing scale up, production monitoring and reporting, and field 
production monitoring and reporting. 
Statement of the Problem 
 Litigation and product recalls are still predominant in a heavily regulated industry 
such as the medical device industry (e.g., Medtronic pacemakers, Baxter pumps, Guidant 
defibrillator and pacemakers).  Medical device manufacturers must be able to select the 
risk management activities that are suitable for their type of product, and employ them at 
phases where they are most appropriate and effective.  This provides industry 
professionals with a basis for identification of potential hazards and means to effectively 
address the risks involved.  The problem is to understand how risk management activities 
currently influence the development of a medical device.  
Research Questions 
 Do regulated risk management activities play a significant role in the medical device 
product development?  
 What is the level of effectiveness of risk management activities in the medical device 
industry?  
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Hypotheses 
 H1: Risk management activities drive the changes in the development of a medical 
device. 
 H0: Risk management activities do not have any impact in the development of a 
medical device. 
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Review of the Literature 
History of Risk Management 
 With no formal regulation to oversee RM, recognition of ISO 14971 and GHTF 
guidance came about in the late 20
th
 century to help medical device manufacturers 
manage the risk associated with their medical device.  The flowchart in Figure 1 depicts 
the evolution of risk management and the associated standards and guidance that support 
the framework of systematically applying risk management activities within the device 
life cycle process. 
Risk Assessment Requirements and Management 
 It is critically important that medical device manufacturers do not only implement 
a full risk assessment process of a medical device but also ensure that a solid risk 
management is also implemented (Medical Device School, 2005).  This way, the 
potential risk of a product can be readily addressed from the time it was being 
conceptualized to the moment when it is released and disposed.  The many regulations 
and standards pertaining to risk management in medical devices, and the establishment of 
the Global Harmonization Task Force (GHTF) whose mission is to harmonize these 
regulations and standards globally, will ease the implementation of the risk management 
process (Global Harmonization Task Force [GHTF], 2009).  GHTF includes Australia, 
Canada, European Union, Japan, and the United States (World Health Organization 
[WHO], 2003). 
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Figure 1: Evolution of RM (G. Rao, personal communication, September 29, 2010) 
GHTF Guidance: 1992 
(inception) 
Harmonize regulations and 
standards globally to ease 
the implementation of risk 
management process. 
 Identify hazards 
including IVD 
 Estimate/Evaluate 
associated risk 
 Control risk 
 Monitor 
effectiveness of 
controls 
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 The international standard for risk management of medical devices is ISO14971.  
The standard covers the risk determination and application activities for the whole life 
cycle of a medical device from design, development, and manufacturing (International 
Organization for Standardization [ISO], 2007).  The risk process determination stated in 
ISO 14971 has two important steps such as the collection and dissemination of 
information.  The collection process engages in quality planning that covers the 
development of risk management plan, identification of potential hazards, estimation, and 
validation of risk.  This information is then disseminated back through design input, 
design output, and design verification.  Risk analysis (hazard identification), risk 
evaluation (risk acceptability), risk control, and risk monitoring (post market 
surveillance) are the critical parts of a medical device risk management (Medical Device 
School,  
2005).  It is also good to take into account that risk analysis and risk evaluation must be 
applied in all phases of the product life cycle (Emergo Group, 2009).  
 Pre-market product control.  Pre-market handles the product’s adherence to 
government regulations and thus falls within the scope of risk management.  Different 
countries have different rules and standards for their product’s approval, however it is the 
same risk management philosophy that governs these requirements, and that is to ensure 
device’s safety and performance (WHO, 2003).  
 According to WHO (2003), the higher the complexity of the design, the higher the 
risk of user error.  It is important that unwarranted risks are avoided at the design and 
conceptualization stage through adequate test validation, verification, and clinical trials.  
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 Manufacturers are also responsible for ensuring that products meet the requirements and 
design specifications.  This is done through good manufacturing management that 
implements the quality system regulations (GHTF, 2009).  Good manufacturing practices 
(GMP) describe the quality system for FDA-regulated medical devices that includes 
process validation and design controls.  These requirements are covered under 21 CFR 
Part 820 of the GMP regulations.  FDA (1987) requires manufacturers to establish 
regulations applicable to their products’ functions, as GMP regulations are broad and 
cover the general product market.  It is the manufacturer’s responsibility to follow the 
procedures suitable to the product being manufactured. GMP also needs to be consistent 
with the requirements set in ISO: 9001 “Quality Systems – Model for Quality Assurance 
in Design, Development, Production, Installation and Servicing” and ISO 13485 “Quality 
Systems – Medical Devices – Supplementary Requirements to ISO 9001 (FDA, 1987).  
 Also included in the pre-market control of a medical device are packaging and 
labeling.  Manufacturers must ensure that safe handling of the device is observed at all 
times to avoid accidental tampering of information on the labels.  The package must be 
well sealed with hazard warnings and clear instructions (WHO, 2003). 
 Placing on-market.  This stage of the life span of a medical device is the 
responsibility of the vendor.  Advertisements are powerful means to convince the users of 
the device’s capabilities to meet their expectations.  Thus, marketing of products must 
also be regulated to avoid mishandling when products are put into their intended use 
(WHO, 2003).  
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 Post-market surveillance.  User error is considered the most common cause of 
death or injury related to medical devices, according to WHO (2003).  It is stated in ISO 
13485 and FDA that companies must have processes in place to obtain customer 
feedback for trend monitoring and data review (Emergo Group, 2009).  It is also noted 
that for the process to be effective, a regular review meeting must be held so that updates 
are disseminated and corrective and preventive actions (CAPA) are implemented when 
necessary.  Data may also include product and process non-conformances, complaints, 
and customer survey.  According to ISO 14971, post market surveillance should include 
the following (Emergo Group, 2009): 
 Systematic process for product evaluation including customer complaints. 
 New hazard evaluation. 
 Objective evidence contained in the file for risk management. 
 Determination of changes, if any, in the acceptance of the original risk. 
 Revisions and feedback to the risk assessment and management as required. 
 In addition to monitoring the products risk it is important to note that a proof of 
documentation that shows how the data are analyzed, inspected, and studied must be 
readily on hand.  It must also include information on who performs the investigation and 
how many times this process is performed.  It is important that the medical devices 
industry has this on-going process for post surveillance trending and reporting of the 
product’s condition to reaffirm its safety and be able to act suitably on any adverse 
effects that they may inflict on the user (Rodriguez, 2009).  
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 Figure 2 (WHO, 2003) shows the life span of a medical device from conception to 
disposal.  It also depicts the party responsible for ensuring that regulations are addressed 
appropriately to reduce, if not eliminate, potential risk through proper monitoring of the 
safety and performance of the device even after sale.  An effective risk management 
emphasizes the different assignments for the responsible people in each stage of the life 
cycle.  WHO (2003) also noted that product and use are the two critical elements that 
guarantee the safety and performance of a medical device.  Pre-market review governs 
product control while the post market surveillance ensures its use to be continuously safe 
and effective.  The placing on-market process in between which includes packaging, 
labeling, advertising and sale avoids misrepresentation.  It is responsible to let the user 
know the device’s intended use.
 
 
Figure 2: Stages of a medical device life span (WHO, 2003) 
 The regulatory framework in Table 1 summarizes the most common activities that 
require regulations in medical device.  The different stages were tabulated with 
identification of the person in charge for controlling and monitoring the device, sale, after 
sale, and use. 
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Table 1: Common regulatory framework for medical device (WHO, 2003) 
Stage Pre-Market Placing On-Market Post-Market 
Control/Monitor Product Sale After-Sale/Use 
Person Manufacturer Vendor Vendor/User 
Items or Activities 
Regulated 
Device Attributes 
- Safety and 
performance 
Establishment 
Registration 
- List products 
available or in use. 
- Requires vendor to 
fulfill after-sale 
obligations. 
Surveillance/Vigilance 
- After-sale 
obligations. 
- Monitoring of 
device’s clinical 
performance. 
- Problem 
identification and 
alerts. 
Manufacturing 
- Quality systems 
 Labeling 
(representation) 
- Accurate 
description of 
product. 
- Instructions for use. 
Advertising 
(representation) 
- Prohibits misleading 
or fraudulent 
advertisement. 
 
 
Product Development Process 
 The product development process of a medical device ensures that the device 
delivered to the customer has gone through rigorous steps to guarantee quality, safety and 
reliability.  It is important that product requirements are clear so that design controls are 
defined and established.  Design control as described by Gopalaswamy & Justiniano 
(2003) is “a set of disciplines, practices, and procedures incorporated into the design and 
development process of medical devices and their associated manufacturing processes”.  
Discipline is what administers the performance of the design activities to be able to 
practice them as appropriate.  The procedures, on the other hand, are the step-by-step 
guidelines that are followed accordingly.  These set of controls, as well as the design 
inputs, are then converted into System Requirements Specifications (SRS), which are 
documented and maintained in the Design History File (DHF), together with the other 
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important processes.  Production of the device comes forth when the final product and 
process specifications are completed and verified in conformance with the design 
controls and SRS.  Risk management is performed alongside the design and development 
process to guarantee that the device being produced does not impose hazards onto the 
user (Gopalaswamy & Justiniano, 2003).   
 Product requirements.  The concept and development phase of product 
development contains the product requirements.  Product requirements define the 
product’s intended use and the target users.  The requirements should also cover the 
following: device characteristics, quality and regulatory requirements, manufacturability, 
human factors, reliability, labeling, packaging, and all the other pertinent information that 
the designers find necessary to start the project.  Information is obtainable from different 
sources like interviews, research studies, past records or device history, and regulatory 
requirements (Fries & King, 2009). 
 Design and development planning.  Design and development planning includes 
program goals and the design and development elements.  The plan details the ways to 
strategically align the team and the resources in terms of the needs defined by the product 
requirements.  The plan contains the schedule of how each action item should be 
executed to meet the requirements.  The plan is properly documented in the DHF.  It has 
to be regularly updated so that every member of the team is attuned to the changes made 
until implementation is performed.  Goals and objectives must also be clearly defined.  It 
is usually the Program Manager’s job to define the objective and to make sure that the 
plan is executed as defined, and that the scope, size, and complexity of the development 
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project are accurately addressed and understood.  Revisions are signed and approved, and 
recorded for proper tracking (Fries & King, 2009).  
 Design and Development Elements 
 Design inputs.  The needs and requirements of the users are converted into 
practical and technical design inputs. 
 Design activities.  Refer to all activities that are performed in the product 
development.  May involve activities related to suppliers and contractors, or activities 
that involve contingencies. 
 Design outputs.  Determines activities to be developed for the desired design 
output.  Accuracy and reliability must be defined with tolerance limits.  Design outputs 
must also address quality, safety, and other factors as appropriate that are defined by 
design and risk analysis. 
 Formal design reviews.  Identify the timing, content and reviewers for a formal 
design review.  Every product must have at least one formal review to assess, at the very 
least, the completed design inputs, outputs, and design validation.  Design reviews should 
also cover design issues and resolutions. 
 Design verification and test methods. Provides evidence that the required 
development activities have been met and that the design outputs meets the design inputs.  
Statistical techniques are employed at this stage.  Includes integration testing, functional 
testing, and biocompatibility.  Data analysis should cover design tolerance, worst-case 
scenarios, thermal analysis, as well as the outputs of risk analysis techniques like FMEA 
and FTA. 
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 Design verification report.  Contains the summary of design verification 
activities, device history file, and all issues that were identified and resolved. 
 Design validation.  Provides validation activities on the project development 
activities performed like validation of test plans, test methods, software validation, risk 
analysis, validation of labeling and packaging, reporting, and reviewing.  User’s needs 
and the device’s intended use are also part of design validation activities.  The purpose is 
to determine discrepancies that may result between production and manufacturing units 
when operated in a simulated condition.  Records and results of these activities are 
contained in the design validation report, which also includes information on the methods 
used and identification of the individuals who performed the validation.  All these and 
other references reside in the device history file. 
 Design transfer.  Design is transferred to manufacturing, service, production, or 
site location. 
 Design change control.  Covers the criteria and responsibilities when approving a 
design change. 
 Device history file (DHF).  This is where all program project records reside to 
provide ease of accessibility for everyone in the team.  It contains previous DHF, 
revisions, and updates. 
 Risk management.  Includes activities for risk management that involves hazard 
identification and detection of the degree of risk to the users. 
 System requirement specification (SRS).  Details of the product design are 
translated into system requirement specifications, which also include inputs from the 
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activities performed in risk management.  SRS requirements include (1) functional 
requirements that define the operational capabilities of the device, (2) physical and 
performance requirements that measure how well the device performs in terms of speed, 
strength, and reliability, (3) interface requirements define the criticality and compatibility 
of the device to its external interface, which includes the users, (4) system architecture 
denotes relationships of the various systems and their requirements, and if applicable, (5) 
software requirements for the product’s functionality that will need to be implemented 
through software.  SRS must also include the following as appropriate: toxicity, risk 
management, biocompatibility, EMC, human factors, etc.  
Risk Assessment Process 
There are four integral steps in the risk assessment process.  They are hazard 
identification, dose-response assessment, exposure assessment, and risk characterization 
(Cammack, Eyre, White &Wilson, 1999).  
 Hazard identification.  Hazard identification is the process that involves the 
determination of any adverse health condition upon exposure to an agent (e.g. chemicals).  
Birth defects, cancer, decreased fertility, and thyroid dysfunction are just few of the cited 
effects of one’s exposure to toxicants (EM-Com, n.d.).  Hazards may be identified using 
one of the following methods: (1) Epidemiological investigation, a study of the frequency 
and distribution of diseases within human population.  It has the advantage of knowing 
and measuring the risk hazards that have direct effects on human (Daniels, Flanders & 
Greenberg, 2005).  (2) Toxicological studies. It is a method of measuring health hazards 
affecting living organism.  It is usually conducted in a controlled environment like the 
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laboratory.  Animals are used for conducting the test (EM-Com, n.d.).  (3) Ecological 
studies. This is a method of determining hazards based on the ecological studies of 
wildlife.  It is believed that potential endocrine disrupters that have adverse affect on 
animals may be potentially harmful to human as well (EM-Com, n.d.). 
 Dose-response assessment.  “All substances are poisons: there is none which is 
not a poison. The right dose differentiates a poison and a remedy. Paracelsus (1493-
1541)” (EM-Com, n.d.).  The characterization of dose-response relationship involves 
determination of the amount of agent that will not cause an effect.  This is the 
determination of the upper limit, which is also called as the “allowable limit” (Gad & 
McCord, 2008).  The response to the agent varies depending on the level of exposure, 
duration of contact or the agent’s level of toxicity (Cammack et al., 1999). 
 Exposure assessment.  This is the estimation of the quantifiable dose of human 
exposure to an existing agent.  Estimation includes that of the duration, frequency, and 
intensity of exposure (Gad & McCord, 2008).  One’s exposure to different toxicants may 
come from the different sources in the environment, which may be synthetic or natural 
occurring.  Synthetic sources of endocrine toxicants can be categorized as voluntary or 
involuntary exposure.  The former includes exposure to commercial products like 
pesticides, cosmetics or medications.  The latter may come from contamination in water, 
air or contact in the contaminated soil (EM-Com, n.d.). 
 Routes of exposure in the human body differ according to the chemical properties 
and human biology.  Routes of exposure can be dermal (skin-absorbed), respiratory 
(inhaled), and gastrointestinal (ingested).  Chemical toxicants that are insoluble in water 
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like PCB’s can be skin absorbed while chemicals that are volatile can be inhaled.  Once 
contaminants enter the body, they travel to organs and tissues through bloodstream.  The 
measure of exposure to chemical contaminants in the body is done through blood 
sampling (EM-Com, n.d.). 
 Risk characterization.  The final step of the risk assessment process includes the 
evaluations and results of the previous three steps.  Risk characterization measures the 
overall risk of the agent towards human exposure.  The allowable limit is then compared 
to the estimated limit of adverse health effects that determines the agent’s safety (Gad & 
McCord, 2008).  
 Risk estimation is assessed in direct proportion for both levels of hazard and 
exposure.  The presence of both assessments constitutes an end result that determines the 
amount of risk involved.  If a hazard exists and the risk is known to be low, then it is an 
acceptable risk.  In the context of the total risk assessment, the uncertainty of the hazard 
level is a pre-defined approach for a more extensive analysis on the amount of hazard 
involved in the compound (Gad & Jayjock, 1988). 
 The four risk assessment steps discussed are vital to the overall assessment of the 
medical device’s exposure to risk.  Thus, it is important to take into consideration the 
accuracy of the test data and results that will determine the device’s acceptable safety 
level for market release. 
Medical Device Classification 
 Part 860 is the medical device classification procedures defined by the Food and 
Drug Administration (2004).  Medical devices are classified according to the potential 
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risk that they may impose on the user and are based on FDA’s level of regulatory control 
to release and market the device.  The higher the class, the higher is the risk and the 
higher is the number of regulatory controls.  
 Class I devices are considered the lowest risk devices as their design is not 
complicated; they are simple to manufacture and safe to users.  These devices do not have 
histories of possible damages and are only subject to general controls.  They also do not 
usually require pre market notification, as general controls are sufficient enough to 
guarantee their safety and effectiveness.  FDA (2004) defines general controls as the 
inclusion of the following: “section 501 (adulteration), 502 (misbranding), 510 
(registration), 516 (banned devices), 518 (notification and other remedies), 519 (records 
and reports), and 520 (general provisions) of the federal food, drug, and cosmetic act”.  
Devices like handheld surgical instruments are considered Class I, as they are not life 
supporting devices (LEEDer Group, 2009).  
 Class II requires general controls and special controls.  Devices under Class II are 
riskier than Class I and may be used for supporting human life.  Thus, FDA (2004) 
requires manufacturers to fulfill sufficient evidence that these devices are assured to be 
safe and effective by establishing the following: proliferation of performance standards, 
post market surveillance, patient registries, development, and distribution of guidance 
documents that include pre market notification according to 510(K) act for market 
submission.  More actions and evidence may be requested by the Commissioner should 
the manufacturer fail to build strong proof that the device is safe for use.  Examples of 
Class II devices are x ray, pumps, and surgical drapes (LEEDer Group, 2009).  
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 Class III devices are the riskiest among the classes of medical device as these 
devices are used for sustaining human life.  Examples are replacement heart valves and 
silicone gel-filled breast implants. Devices under this category are usually required to 
have both a Pre-Market Approval (PMA) and 510(K) clearance for market submission 
(FDA, 2004).  The Commissioner may also require additional evidence of safety and 
effectiveness when deemed necessary. 
United States Regulatory Pathway 
 Regulatory requirements for clinical trials.  The International Review Board 
(IRB) is defined as “…any board, committee, or other group formally designated by an 
institution to review, to approve the initiation of, and to conduct periodic review of, 
biomedical research involving human subjects. The primary purpose of such review is to 
assure the protection of the rights and welfare of human subjects” (Segal, 1998).  IRB 
ensures that the rights of the subject matter are protected and that their risk to potential 
hazards is minimized.  IRB also has the authority to grant approval or disapproval, to 
continue or discontinue a clinical trial.  All clinical trials must be conducted according to 
the Investigational Device Exemption (IDE) regulations. Devices exempted from IDE 
regulations include pre amendment and SE devices, with provisions that they are not 
transitional devices and were investigated according to the labeling that was FDA 
reviewed at that time.  An IDE application that was approved by FDA is required prior to 
a clinical trial on a device that has a significant risk.  All approved clinical trials must be 
performed in accordance with the Good Clinical Practices (GCP).  GCP refers to the 
approved standards and federal regulations relating to clinical studies that include 
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reporting and record keeping requirements, gathering of scientific data, subject’s 
informed consent, and data that contains safety and effectiveness information required by 
the regulatory bodies.  A standardized GCP called Guideline on Good Clinical Practice 
was formed by the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use to have a standardized 
set of guidelines for the U.S., European Union, Japan, Australia, Canada, the Nordic 
countries and WHO (Segal, 1998).   
 Significant risk (SR) and non significant risk (NSR) device.  SR device is 
defined as “…an investigational device that presents a potential for serious risk to the 
health, safety, or welfare of a subject and is an implant; or is used in supporting or 
sustaining human life; or is of substantial importance in diagnosing, curing, mitigating 
or treating disease, or otherwise prevents impairment of human health; or otherwise 
presents a potential for serious risk to the health, safety, or welfare of a subject” (Segal, 
1998).  An NSR device, on the other hand, is one that does not meet the description of an 
SR device.  Appendix A shows a list of examples of SR and NSR devices taken from the 
Center for Devices and Radiological Health (CDRH) (2006).  Sponsors and IRB use this 
list in reference to their determination whether a device is SR or NSR.  It is noted though 
that the list under NSR devices may not be considered final because the risk evaluation 
must determine the intended use of the device in a study.  
 The IRB reviews the sponsor’s proposal for a clinical investigation based on the 
device description, investigation plan, reports of past investigations related to the device, 
and the criteria for subject selection.  It is the IRB’s discretion to classify whether a 
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device is SR or NSR.  In this regard, FDA considers that IRB has the standard operating 
procedures (SOP) to conduct the clinical reviews on the subjects being studied for 
diagnostic or treatment purposes.  Data confidentiality, impartial subject selection, a 
documented consent, and sufficient provisions that define the subject’s protection of 
privacy are some of IRB’s conditions for a clinical trial review.  Any risks that may be 
imposed on the subject matter must be proven reasonable for the intention of the benefits 
and knowledge that are achieved at the end of the investigation.  Thus, SR and NSR 
determination is based on the potential harm that may be inflicted on the subject 
participating in the investigation, plus the harm it entails in the use of the device, whereas 
IRB’s approval for implementation of the clinical trial is based on the study’s risk-benefit 
assessment (CDRH, 2006).  
 SR device studies should conform to the regulations set by IDE at 21 CFR 812 
and an approved application from FDA before commencement.  While NSR device 
studies has the abbreviated requirements at 21 CFR 812(b) for compliance (CDRH, 
2006).  Food and Drug Administration (FDA) Reviewing Process. 
 The FDA’s role is to ensure that products released to market have sufficient 
evidence of safety (potential risk) and effectiveness (intended use) through clinical 
investigations conducted in accordance with the rules and regulations of the 
administration.  Appendix B shows the scope of the review type and requirements 
according to the level of submission.  
 Pre-market review.   In May 1976, Congress issued the Medical Device 
Amendments requiring FDA to have all Class III medical devices to go through the PMA 
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process before they can be commercially released.  Devices released before May 1976 
were classified as pre amendment devices while those marketed after were categorized as 
post amendment devices (“Medical Devices: FDA,” 2009).  PMA review is conducted for 
post amendment devices that are deemed non substantially equivalent (NSE) to a pre 
amendment device and should submit adequate clinical investigations for the products 
release.  Either that, or the Class III device will have to be reclassified as Class I or II.  
Substantially equivalent (SE) devices, on the other hand, that have the same intended use 
as the predicate device (pre amendment devices with approved 510(K)) with the same 
technological characteristic (TC), or with different TC but proved to be safe and effective 
as the predicate device, can submit a 510(K) clearance to market (“Medical Devices: 
FDA,” 2009).  A less stringent 510(K) submission is seen to be dominantly favored than 
PMA by most medical device suppliers for grounds of faster turnaround time and 
enormous savings in cost.  Moreover, 510(K) submissions only include comparative 
descriptions that includes performance data, and is more focused on the end product than 
the manufacturing process itself (“Medical Devices: FDA,” 2009).  Table 2 shows 
GAO’s (2009) findings of FDA’s approved devices based on 510(K) and PMA 
submissions comparing turnaround time and cost.  
 Post-market surveillance.  FDA’s post market surveillance guarantees that 
devices remain safe and effective after they are released to the market through the 
analysis of the annual reports that were submitted to them by users and manufacturers.  
Reports include serious device related injuries, device malfunctions, and death (“Medical 
Devices: Shortcoming,” 2009).  
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 FDA agents are responsible for the research and investigation of issue trends in 
relation to the medical device safety, while FDA scientists are in charge for the review 
and follow up investigations based on the initial reports received. FDA scientists will 
issue necessary steps and actions for issue resolution and they can also issue product 
recalls, advisories or even require the manufacturers to change instructions in their device 
labeling as necessary (“Medical Devices: Shortcoming,” 2009). 
Table 2: 510(K) and PMA Submission Comparison (“Medical Devices: FDA,” 2009) 
 Turnaround time 
(based on 2009 data) 
Cost 
 FDA reviewing 
submission (FY 2005) 
Applicant submission  
(FY 2009) 
510(K) 
Submission 
90% within 90 days $ 18, 200 $ 3,693 
98% within 150 days 
PMA 
Submission 
60% in 180 days $ 870,000 $ 200,725 
90% in 295 days 
 
 Inspection of manufacturing establishments.  For both pre market and post 
market supervision of medical devices, FDA also takes responsibility in making sure that 
the manufacturing establishments strictly follow the standard manufacturing requirements 
for device safety and effectiveness, and that local and international requirements are 
properly accounted for.  It is also required that they inspect Class II and III device 
manufacturing establishments every two years (“Medical Devices: Shortcoming,” 2009). 
 The provisions included in Congress’ Medical Device User Free and 
Modernization Act of 2002 (MDUFMA) was instituted to support and increase the 
number of manufacturing establishments that are FDA inspected and to help 
manufacturers perform a single inspection that will cover both local and international 
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requirements.  In response to these provisions, FDA formed the Accredited Persons 
Inspection Program and the Pilot Multi-purpose Audit Program (with Health Canada) that 
will allow manufacturers to acquire inspection services that will ease their compliance to 
the governing requirements in the US and abroad, as well as reduce the cost that would 
have been incurred if it were done in multiple inspections.  (“Medical Devices: 
Shortcoming,” 2009).  
Risk Analysis Techniques 
 Risk analysis is a fundamental requirement in the submission checklist for PMA 
and 510(K) and a significant guideline contained in GMP.  The hazardous effects of a 
device are of great consideration before a product is approved for market release.  Thus, 
the law requires the inclusion of risk analysis in the design phase of a medical device for 
early detection of adverse events that can cause serious harm to the user (Kamm, 2005). 
 Systematic methods for identifying and measuring the potential risk or hazard are 
specified in Annex G.6 of ISO 14971.  These tools are used to effectively carry out the 
risk analysis of a medical device.  Utilization of more than one tool may be necessary on 
an event that requires it (ISO, 2007).  
 Preliminary Hazard Analysis (PHA).  PHA is a method of identifying potential 
hazards at the very early stage of design where a more extensive approach may not be 
suitable.  It is importantly useful in the analysis of systems where preliminary design is 
underway as it identifies the harmful effects caused by an event or a situation.  This helps 
lead the designers to take the steps necessary to alleviate the system’s or activity’s 
potential risk.  Other names that are associated to PHA are Rapid Risk Ranking and 
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Hazard Identification (HAZID) (Rausand, 2005).  PHA risk analysis takes the following 
characteristics into consideration: system interfaces, equipment used, environmental 
constraints, layout, and hazardous components (ISO, 2007). A typical PHA worksheet is 
shown in Appendix C.  
 The PHA risk analysis process can be broken down into four steps: (1) 
Establishment of PHA requirements, (2) Identification of potential hazard, (3) 
Measurement of frequency of occurrence and its severity, and (4) Risk ranking (Rausand, 
2005).  
 Establishment of PHA requirements.  PHA involves formation of the analysis 
team.  This team should be able to clearly define and describe the potential problem 
according to system, equipment, environment, layout, and components involved and the 
subject being analyzed.  The team must document the measures for detection and 
prevention for the establishment of design controls.  Supporting data taken from past 
cases with related events are also good sources for investigation.  
 Identification of potential hazard.  Every factor that is likely to cause danger 
must be identified.  The list can go from maintenance operations to system safety, etc.  
 Measurement of frequency of occurrence and its severity.  Events are ranked 
based on the severity of the failure outcome and the frequency of this outcome.   
 Risk ranking.  Three categories (critical, major, minor) define the severity of 
failure in the PHA matrix and they are tabulated against the estimated frequency of 
occurrence.  Recommended actions are based on the acceptability level. 
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 The “as low as reasonably practicable” (ALARP) principle is the action 
determined for fairly acceptable cases.  These are considered low-level risks that do not 
need further actions.  The medium level acceptable situations will require further 
investigations and verification of the effectiveness of the corrective actions.  A 
reassessment of the risk score may be required to verify improvements.  The high-level or 
unacceptable risks take on the more rigorous actions to address the potential hazards 
involved.  Verification of corrective actions is a requirement for risk reassessment.  
 The PHA process of risk analysis supports design resources like time and cost as 
it helps to ensure that potential risks are identified at the earliest time possible.  However, 
it is also a challenge for designers to execute the plan of performing PHA as hazard 
interactions may not be easily recognizable and potential hazards may not always be 
foreseeable (Rausand, 2005).  
 Usability Engineering/Human Factors.  Usability Engineering or Human 
Factors is a process of designing a device with high consideration on human accessibility 
and compatibility.  Meeting the needs of the users and at the same time taking into 
account the standards and regulations that govern design implementation.  Many 
companies now employ usability engineering into the product life cycle as it covers a 
systematic approach to design techniques and vast information on human characteristics. 
Greater customer satisfaction is also highly anticipated by companies that employ this 
technique.  Users play a significant role through interview, user feedback and survey 
(Wiklund, 1995). 
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 User studies.  Most medical device manufacturers employ focus groups that study 
the type of users of the device.  They are formed to study the needs of the users, how they 
will use the device, and how often the users will use the device.  Interviews and survey 
questionnaires are often employed by the focus groups to obtain answers to these 
questions that will significantly help in getting the usability testing started.  
 Usability goal setting.  This is the step wherein usability goals are defined and 
then compared to the design goals set.  It usually involves a team of people who makes 
the realistic assessment of obtaining usability goals that will fit the design and vice versa. 
 Concept development.  This step includes exploration of mental concepts, 
establishment of a user interface structure, concept modeling, and evaluation.  
 Detailed design.  A realistic design is developed in this stage.  All things 
considered such as usability test results, modeling, and evaluation. 
 Specification.  Proper documentation of instructions and manuals is addressed in 
this step.  Include drawings, reports and user interface descriptions. 
 Field activities.  The practical use of the actual device is evaluated and user 
feedback is obtained.  According to studies, most nurses make usability a requirement 
before actually using a device.  
 Though the usability test can be planned and performed in the various phases of 
the device life cycle, it is most effectively conducted when a device is ready to market 
and has proven reliable in meeting the customer’s needs.  A prototype of the actual 
device is more appropriately suitable to perform the test to get accurate information on 
the user’s perspective on the device’s ease of use and compatibility.  Test plan should 
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include the objective, type of data to be collected, number, and type of test subjects, and 
upon completing these steps, the documented analysis of test results.  Test objectives may 
contain collection of user’s inputs on device improvement, determination of the device 
more preferred by the user and development of baseline upon user performance. Baseline 
considers incident and success rate and completion time.  The place where the design 
must be conducted must also be defined be it in an office environment or a laboratory set 
up.  Data analysis may employ statistical tools that can effectively separate the problems 
from successes like comparison of the mean and standard deviation.  The use of statistical 
analysis makes it easier to convey the necessary information.  Finally, usability report 
must cover a summary of the test results and recommendations for design improvement 
when appropriate (Wiklund, 1995).  
 Fault Tree Analysis (FTA).  FTA is a top down approach of problem solving 
(O’Connor, 2002).  It starts with identifying the potential hazard and breaks it down to 
failure modes that may have caused the hazard.  This approach uses logic gates like “and” 
and “or” gates to relate potential failures to possible causes.  It provides a systematic 
approach to problem solving as it visually details the causes and effects of activities or 
human related factors that may have caused a high level of risk if overlooked (Kamm, 
2005).  The tree like representation of root cause analysis gives the reviewer a clear 
picture, at a glance, of each of the possible scenarios that is taken into consideration.  For 
large complex systems where failure modes may be enormous, software programs are 
now available to aid organizations in doing FTA (O’Connor, 2002).  
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 FTA steps include the list of possible hazards like injury, electric shocks, and fire, 
and the identification of failures and failure modes that may have resulted in these 
hazards.  Construction of a fault tree diagram may begin with these lists, and elimination 
of unacceptable events may then be carried out.  
 Failure Mode and Effects Analysis (FMEA)/Failure Mode, Effects, and 
Criticality Analysis (FMECA).  Contrary to FTA, FMEA uses a bottom up approach of 
problem solving.  It is performed in the early stage of design development, usually at the 
feasibility stage, to assess every component’s possible risk (Bhote & Bhote, 2004).  A 
component level assessment gives designers ideas on what they can improve in the 
design to improve the product’s reliability and make it less susceptible to harmful 
failures.  The failure modes and their severity are assessed based on risk index that will 
also determine the necessary actions for improvement, and this is where the term 
FMECA comes into play (Kamm, 2005).  The two types of FMEA are Design FMEA 
(DFMEA) and process FMEA (PFMEA).  DFMEA deals with design inadequacies and 
their effect on manufacturing operations, while PFMEA assesses the potential risks that 
may possibly transpire in the plant. While these two types have various potential 
problems that are different from each other, the FMEA approach is still similar, and takes 
into account the early signs of failure to avoid further changes on the later part of the 
design or process (Kamm, 2005).  FMEA process steps include definition of the system 
being analyzed, identification of the failure modes and their effects associated with the 
system or component being investigated, measurement of risk index, and determination 
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of corrective and preventive actions for improvement. Implementation of these actions 
must be monitored to ensure that desired output is met (Kamm, 2005).   
 FMEA uses risk index to determine the severity of the failure.  It is calculated 
based on the probability of occurrence versus the severity.  The final score will reveal the 
acceptability criteria most suitable to the level of hazard of the failure mode (Kamm, 
2005).  Safety precautions that are significantly beneficial to using the FMEA in 
preliminary design include the use of sound judgment of the designer to only include the 
most unreliable parts and their potential failures.  The attention is focused on the 
corrective actions that contribute most significantly in determining the part’s reliability 
(Bhote & Bhote, 2004) 
 Hazard and Operability Study (HAZOP).  HAZOP is a team approach problem 
solving method.  It involves people with different expertise whose conviction of the 
process or system that is analyzed is what makes the HAZOP analysis effective and 
easily carried out.   
 The purpose is to identify the potential hazards that can come out of the system in 
review, and to be able to identify the methods and actions necessary to minimize the 
hazards (ISO, 2007).  Guide words like “no/not, more, less, as well as, part of, reverse 
and other than” help to describe the failure or design deviation (O’Connor, 2002).  The 
objectives of HAZOP analysis are to provide a full description of the medical device and 
its intended use, to review each of the intended use and determine how design deviations 
can possibly occur in each of the intended use.  It is important to know the consequences 
of these deviations that can lead to possible hazards (ISO, 2007). 
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 Hazard Analysis and Critical Control Point (HACCP).  HACCP is a 
systematic approach for identifying, evaluating, controlling and monitoring of possible 
hazards that take place in the different life cycles of a medical device.  Life cycle stages 
include design, manufacturing, service, use and disposal.  HACCP is typically used in the 
latter part of the design phase to optimize design changes (ISO, 2007).  HACCP is an 
approach that was first used by NASA to monitor food poisoning of the food being 
supplied to their astronauts, and was later adapted by WHO to include in the risk analysis 
methodology for drugs and pharmaceutical products (T. Chan, personal communication). 
HACCP’s seven guiding principles as defined by ISO (2007) include: (1) Carry out a 
hazard analysis and identify preventive measures, (2) Determine critical control points 
(CCP’s), (3) Generate critical limits, (4) Create a system for CCP monitoring, (5) 
Establish corrective actions for out of control CCP’s, (6) Generate procedures for 
verification of HACCP effectiveness, and (7) Establish documentation and record 
keeping.  An effective HACCP system is governed by continuous controlling and 
monitoring of the hazards identified (principles 2, 3 and 4), the manufacturer’s ability to 
ensure that the system is in control and that corrective measures are effectively in place 
(principles 5 and 6), and establishment of effective documentation that includes process 
flowcharts, hazard analysis worksheet and HACCP plan.  The process flowchart should 
be able to clearly describe the process as it serves as a guide to the team who is reviewing 
it.  It is important that a step-by-step description of the process is stated for better 
understanding of the methods incorporated within.  The hazard analysis worksheet 
contains the hazards that were identified in the process and their significance.  A list of 
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the control measures, including the CCP’s, is also visible in the analysis worksheet.  The 
HACCP plan is formulated based on the seven principles and ensures that proper control 
is in place for the control and implementation of the procedures in relation to design, 
products, processes or procedures (ISO, 2007).  Benefits include great reduction of 
customer complaints and product recalls, better time management as downtime is 
reduced, and increase employee awareness of process controls with ownership of product 
safety and effectiveness (T. Chan, personal communication). 
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Methodology 
 The survey design was established through the help of an industry expert, Dr. 
Geetha Rao, who also helped in the data analysis.  Three medical device professionals 
were selected to validate the survey design and do a trial run.  The feedback gathered 
from these 3 respondents helped to revise the survey with particular considerations on the 
number of questions, the type of questions asked, the time allotment to complete the 
survey, and the method to answer the survey. 
 Final revision of the survey is provided in Appendix D.  This survey was posted 
online using Survey Monkey.  It was designed as a 10-minute online survey consisting of 
22 questions.  The questions were divided into three sections: introduction (about the 
medical company), information on a selected medical device, and risk management 
assessment.   
 The actual email that was used to invite medical device professionals to 
participate in the survey is provided in Appendix E.  This email, which also contains the 
link to the survey was initially distributed privately in March 2010 to 20 individuals who 
work at medical device companies or whose work is associated with medical devices.  
Later the survey was distributed more broadly through ASQ-NCBDG (American Society 
for Quality – Northern California Biomedical Discussion Group) out to its 400-member 
mailing list.  
Answers to the survey were gathered over a period of two months. There were a 
total of 41 responses received over the total 3-month period. Sixteen of the respondents 
completed the entire survey but of those only 14 responses were considered valid as 2 of 
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the survey respondents either misunderstood a question or mistakenly answered a 
question on the rate of the effectiveness of RM.  One out of the 14 respondents did not 
provide a clear definition of the medical type so only 13 medical device types were 
identified. 
 Qualitative data analysis for this type of non-experimental design was utilized, 
with supporting charts and tables to present the actual results gathered from the survey.  
Analysis charts were created for the following: 
 The degree of change of the risk analysis technique used at every phase of the device 
life cycle. 
 The effectiveness of the risk analysis technique used at each phase. 
Data Analysis 
 With the different variables (development phase, RM activity, degree of change, 
effectiveness) that are factored in, it was initially difficult to discern the significance of 
each variable and come up with any immediate conclusion. Intermediate data analysis 
was used as a part of the initial assessment for the varying results gathered from the 
survey.  The initial data analysis helped gauge whether the results that were collected 
would be able to provide any justification to the hypotheses.  The results indicated some 
evidence to support the hypothesis that RM activities have an impact, but this was not 
true across the board.  More detailed analysis was performed to understand the impact 
more granularly.  The conclusions established from the survey results were done based on 
the method described in the Final Data Analysis. 
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 Intermediate data analysis.  Individual responses on risk management 
assessment (degree of change and effectiveness) were tabulated against the RM activities 
performed during each phase (see Appendices F1 to F9, and G1 to G9 for charts).  
 A numerical value was assigned to rate the effectiveness: 5 (high), 3 (medium), 
and 1 (low).  The scores on effectiveness were based on the number of times the RM 
activity was used (implementation) at every phase, and the respondents’ individual rating 
of its effectiveness (calculated).  The scores provided an indication of how the different 
techniques can contribute to a change in design, manufacturing, and labeling. 
 Implementation score is the frequency of use of the RM activity at each phase, 
while effectiveness score was calculated by using the following formula: Sum of the rate 
of effectiveness / Implementation score. 
 For example, in the Conceptualization phase, 4 medical device professionals are 
using Hazard ID/PHA.  The following ratings were obtained for the risk analysis 
technique’s effectiveness in catching problems: two 5’s (high) and two 1’s (low).  What 
is the effectiveness score? 
 Implementation score = 4 
 Sum of the Rate of Effectiveness = 5 + 5 + 1 + 1 = 12 
 Effectiveness score = Sum of the rate of effectiveness / Implementation score 
 Effectiveness score = 12 / 4 = 3.0 
 Thus, the effectiveness score of the risk analysis technique, Hazard ID/PHA in 
catching problems is 3 at the Conceptualization phase.  A score of 3 means that Hazard 
ID/PHA is moderately effective in catching problems at the Conceptualization phase.  
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 Final data analysis.  A color coding scheme was used to distinguish the type of 
change that happened over the device’s life cycle, as well as to rate the effectiveness of 
the RM activities for the following factors: catching problems, early identification of 
potential risk, identification of product improvements, saving cost, and overall design 
quality.  Figures 3 to 16 show the charts for the 14 individual responses.  
 Degree of change.  The number of labeling, design and manufacturing changes 
were counted and tabulated for each of the development phase.  Colors used for the type 
of change are as follows: orange for labeling change, blue for design change, and brown 
for changes in manufacturing.  The number of times (Y-axis) the type of change occurs at 
each phase tells us how much of the RM activities can contribute to these types of 
changes in the medical device life cycle. 
 Effectiveness.  Effectiveness was rated high (red), medium (yellow) or low 
(green).  The ratings were tabulated for each of the development phase, and put into a 
chart incorporating the colors associated with the ratings.  The colors indicate the effect 
of the RM activities for the following factors: catching problems, early identification of 
potential risk, identification of product improvements, saving cost, and overall design 
quality. 
 This color coding scheme has helped to visualize a pattern on how effectiveness is 
rated high on some or all of the factors during the early stages, and how the ratings are 
shifted from high to low during the post-market stage.  As the individual charts were laid 
out, common trends were observed on the effectiveness ratings based on three factors: 
medical device type, device development history and the time since the device was 
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market released.  This led to the conclusion that the effectiveness of RM activities is 
significantly impacted by these three factors.  
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Discussion 
Survey Findings  
 See Appendix H1 to H11 for the complete survey findings and results. The 
medical device industry is comprised of a wide range of functions that provides for the 
many different needs of the consumer population.  The survey results revealed a high 
number of medical device manufacturers that comprised 73.7% of the total survey 
respondents.  Medical device marketers placed as the second highest with 39.5%.  Other 
groups of medical device professionals belong to component and service providers, 
wherein service providers are either consultants or educators.  The responses gathered 
from the survey were able to create the necessary evidence that helps to validate our 
claim that the selection of risk analysis techniques over the life cycle of a medical device 
provides medical device manufacturers the needed confidence to effectively carry out a 
successful risk management.  The percentage of respondents that perform risk 
management at their work place is 95%.  The remaining 5% do not necessarily need to do 
risk management, as they are involved with either a consulting firm or an educational 
institution.  This is, therefore, solid evidence that risk management is an activity 
performed in the medical device industry. 
 ISO 14971 is the international standard for risk management in the medical device 
industry.  The standard provides a high level assessment of identifying, controlling, 
assessing, and accepting risk.  About 83% of the respondents use ISO 14971 (2000, 
2007). ISO 13845, which is the international standard for medical device quality system 
regulation, is as well observed to a great extent, with 84% of the respondents claiming 
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they are compliant.  ICH Q9 compliant is 9.7%.  One of the observations noted was how 
some respondents may have confused standards from guidance documents as revealed in 
survey question number 5, where others regarded ISO 14971 and ISO 13485 as guidance 
documents instead of standards.  Industry awareness of standards therefore, needs to 
improve.  
 Survey results show 46% of the total population, operate with more than 5 
product lines.  While 33% have 2 to 5 product lines, and 7% with 1 product line. Other 
survey respondents skipped this question. 
 The foremost important aspect of this study is to know how the different risk 
management techniques affect the overall implementation of risk management 
throughout the device’s life cycle.  The degree of change and effectiveness brought about 
by the RM techniques were evaluated.  A closer look at these three factors: (1) medical 
device type, (2) device development history, and (3) time since market release, have 
shown significant impact on these factors, which have also made this study more 
comprehensive. 
 Medical device types were divided into four categories: (1) surgical tools and 
catheters, (2) diagnostic devices, (3) implantables, and (4) other therapeutic devices.  A 
total of 14 responses were analyzed based on the three significant factors mentioned, with 
focus on the degree of change and rate of effectiveness. Here is the breakdown of the 
medical device type of the 14 respondents:  
 4 Surgical tools and catheters 
 3 Diagnostic devices 
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 5 Implantable devices 
 1 Other therapeutic device 
 1 Unknown (respondent was not clear on the medical device type) 
 Twelve out of 14 have rated the effectiveness of the risk management techniques 
used, while 13 were able to measure the degree of change.  The preceding charts (Figures 
3 to 16) show the individual assessments of the 14 survey respondents on the degree of 
change and rate of effectiveness of RM in catching problems, early identification of 
potential risk, identification of product improvements, saving cost, and overall design 
quality.  Table 3 is the summary of results and observations gathered based on the survey 
response. 
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Medical Device Type: 
Surgical/Clinical Tools 
 
Approximate Time Since Market Release: 
6 months to 18 months 
 
Device Development History: 
Revision of previous first generation device 
 
 
 
Figure 3: Degree of change and RM effectiveness assessment (Respondent no. 1) 
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Medical Device Type: 
Surgical/Clinical Tools 
 
Approximate Time Since Market Release: 
Unknown 
 
Device Development History: 
Unknown 
 
(No response on the degree of change) 
 
 
Figure 4: Degree of change and RM effectiveness assessment (Respondent no. 2) 
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Medical Device Type: 
Other (please specify) - 
Catheters 
Approximate Time Since Market Release: 
18 to 36 months 
Device Development History: 
New, first generation device marketed for first time 
 
Figure 5: Degree of change and RM effectiveness assessment (Respondent no. 3) 
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Medical Device Type: 
Surgical/Clinical Tools 
Instrument Disposable 
Approximate Time Since Market Release: 
6 months to 18 months 
 
Device Development History: 
Revision of previous first generation device 
 
 
 
 
Figure 6: Degree of change and RM effectiveness assessment (Respondent no. 4) 
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Medical Device Type: 
Diagnostic - Ophthalmic Imaging 
Systems 
Approximate Time Since Market Release: 
6 months to 18 months  
Device Development History: 
Third or later generation device 
 
 
 
Figure 7: Degree of change and RM effectiveness assessment (Respondent no. 5) 
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Medical Device Type: 
Surgical/Clinical Tools, 
Diagnostic, Instrument Disposable 
Approximate Time Since Market Release: 
Greater than 3 years  
Device Development History: 
Revision of previous first generation 
device 
 
 
 
Figure 8: Degree of change and RM effectiveness assessment (Respondent no. 6) 
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Medical Device Type: 
Medical Device Type: 
Diagnostic - hematology instruments 
(blood cell counters) 
Approximate Time Since Market Release: 
Greater than 3 years 
Device Development History: 
Revision of previous first generation 
device 
 
Figure 9: Degree of change and RM effectiveness assessment (Respondent no. 7) 
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Medical Device Type: 
Therapeutic 
Diagnostic 
Implantable Electrophysiology at the San Jose 
Campus 
Approximate Time Since Market Release: 
Greater than 3 years 
 
Device Development History: 
New, first generation device marketed for 
first time 
 
(Invalid response for effectiveness) 
 
Figure 10: Degree of change and RM effectiveness assessment (Respondent no. 8) 
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 Medical Device Type: 
Implantable 
Approximate Time Since Market Release: 
Not yet released – in clinical trial 
Device Development History: 
Third or later generation device 
 
 
 
 
Figure 11: Degree of change and RM effectiveness assessment (Respondent no. 9) 
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Medical Device Type: 
Implantable 
Approximate Time Since Market Release: 
Not yet released – in clinical trial 
Device Development History: 
New, first generation device marketed 
for first time 
Figure 12: Degree of change and RM effectiveness assessment (Respondent no. 10) 
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Medical Device Type: 
Therapeutic, Implantable 
Approximate Time Since Market Release: 
Not yet released – in clinical trial 
Device Development History: 
New, first generation device marketed 
for first time 
Figure 13: Degree of change and RM effectiveness assessment (Respondent no. 11) 
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Medical Device Type: 
Implantable 
Approximate Time Since Market Release: 
Not yet released – in clinical trial 
 
Device Development History: 
New, first generation device marketed 
for first time 
  
Figure 14: Degree of change and RM effectiveness assessment (Respondent no. 12) 
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Medical Device Type: 
Therapeutic - investigational device 
for migraine pain 
Approximate Time Since Market Release: 
Not yet released – in clinical trial 
Device Development History: 
New, first generation device marketed 
for first time 
 
Figure 15: Degree of change and RM effectiveness assessment (Respondent no. 13) 
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Medical Device Type: 
Therapeutic 
Surgical/Clinical Tools 
Diagnostic 
Implantable 
Approximate Time Since Market Release: 
18 to 36 months 
Device Development History: 
Revision of previous first generation 
device 
(Invalid responses for effectiveness) 
 
Figure 16: Degree of change and RM effectiveness assessment (Respondent no. 14) 
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 Table 3: Summary of the Effectiveness of RM activities by Respondent 
Respondent 
No. 
Device Type Development 
History 
Time since Market 
Release 
Summary of response  
1 Surgical tool Revision of previous 
first generation device 
 
Greater than 3 years 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 FTA 
 DFMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
Degree of change 
 Design, manufacturing and 
labeling changes during the pre-
market stage. 
Effectiveness of RM 
 Rated high on all factors during 
all pre-market stages.  
2 Surgical tool Unknown Unknown RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
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Data/Customer Feedback 
 
Degree of change 
(No response) 
 
Effectiveness of RM 
 Cost savings was rated high at 
the conceptualization stage.  
 Highly effective in catching 
problems and identification of 
product improvements during 
field-production monitoring and 
reporting. 
3 Other - 
Catheters 
New, first generation 
device marketed for first 
time 
 
18 to 36 months 
 
(Not reliable data for techniques used) 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 FTA 
 DFMEA 
 PFMEA 
 HAZOP 
 HACCP 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 More design changes at both 
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pre-market and post-market 
stages. 
 Design, manufacturing and 
labeling changes at both pre-
market and post-market stages 
 
Effectiveness of RM: 
 Highly effective for all factors 
(except for cost savings) at the 
pre-market stage. 
 Cost savings and overall design 
quality were rated highly 
effective at the post-market 
stage. 
4 Surgical tool Revision of previous 
first generation device 
 
6 to 18 months 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 FTA 
 DFMEA 
 HACCP 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design and labeling changes 
during the early stages. 
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Effectiveness of RM: 
 Highly effective for all factors 
(except for identification of 
product improvements) at the 
earlier stages. 
 Identification of product 
improvements was rated high at 
a later stage. 
5 Diagnostic 
tool 
Third or later generation 
device 
 
6 to 18 months 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 DFMEA 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design and labeling changes at 
V&V and post-market stage. 
 
Effectiveness of RM: 
 Catching problems was rated 
high at both pre- and post-
market stages. 
 Overall design quality is highly 
effective at the pre-market stage. 
 Identification of product 
improvements was rated high at 
a later stage. 
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6 Diagnostic 
tool 
Revision of previous 
first generation device 
 
 Greater than 3 years 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 FTA 
 DFMEA 
 PFMEA 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design changes at initial 
development and V&V. 
 Manufacturing changes at a later 
stage. 
 
Effectiveness of RM: 
 Rated highly effective for all 
factors in the earlier stages. 
 Effectiveness was not indicated 
in the later stages, but it can be 
inferred that RM techniques 
were less effective during those 
stages. 
7 Diagnostic 
tool 
Revision of previous 
first generation device 
 
 Greater than 3 years 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
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 FTA 
 DFMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design, manufacturing and 
labeling changes at the earlier 
stages and at the production 
monitoring & reporting stage 
 
Effectiveness of RM: 
 Early identification of potential 
risk, identification of product 
improvements and overall design 
quality were highly effective 
during conceptualization. 
 All factors were highly effective 
for all factors during initial 
development. 
 Catching problems was rated 
high during manufacturing scale-
up. (No technique identified at 
this stage but effectiveness was 
indicated.) 
8 Implantable New, first generation 
device marketed for first 
time 
 
 Greater than 3 years 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
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Analysis/Use FMEA 
 FTA 
 DFMEA 
 PFMEA 
 HAZOP 
 HACCP 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design was actually evolved.  
 Many later stage changes on 
design, manufacturing and 
labeling. 
 
Effectiveness of RM 
(No response) 
9 Implantable Third or later generation 
device 
 
Not yet released – in 
clinical trial 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 DFMEA 
 PFMEA 
 Risk Benefit Analysis 
 
Degree of change: 
 Early design changes.  
 Manufacturing change during 
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V&V. 
 
Effectiveness of RM 
 Highly effective for all factors 
during the earlier stages of the 
pre-market phase. 
 
10 Implantable New, first generation 
device marketed for first 
time 
 
Not yet released – in 
clinical trial 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Design, manufacturing and 
labeling changes at the pre-
market stage.  
 
Effectiveness of RM 
 RM techniques are highly 
effective for all factors during 
the pre-market stage (except for 
saving cost). 
 
11 Implantable New, first generation 
device marketed for first 
time 
Not yet released – in 
clinical trial 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Human Factors/Usability 
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 Analysis/Use FMEA 
 DFMEA 
 PFMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Labeling and manufacturing 
changes at the pre-market stage.  
 Some design change during 
clinical validation. 
 
Effectiveness of RM 
 Overall design quality is highly 
effective during the pre-market 
stage. 
 Catching problems and early 
identification of product 
improvements were rated highly 
effective during V&V and pilot 
production. 
 
12 Implantable New, first generation 
device marketed for first 
time 
 
Not yet released – in 
clinical trial 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 DFMEA 
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Degree of change: 
 Only labeling changes were 
indicated from V&V. 
 Design and manufacturing 
changes at the initial 
development. 
 
Effectiveness of RM 
 Effectiveness was primarily 
indicated for cost savings and 
overall design quality. 
13 Therapeutic New, first generation 
device marketed for first 
time 
 
Not yet released – in 
clinical trial 
 
RM techniques used: 
 Establish risk acceptance criteria 
 Hazard ID/PHA 
 Human Factors/Usability 
Analysis/Use FMEA 
 DFMEA 
 PFMEA 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Very active design changes in 
RM. 
 
Effectiveness of RM 
 Rated very highly effective. 
14 Unknown Revision of previous 
first generation device 
18 to 36 months 
 
RM techniques used: 
 Establish risk acceptance criteria 
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  Human Factors/Usability 
Analysis/Use FMEA 
 DFMEA 
 HAZOP 
 HACCP 
 Risk Benefit Analysis 
 Risk Assessment of Complaint 
Data/Customer Feedback 
 
Degree of change: 
 Very active design changes in 
RM. 
 
Effectiveness of RM 
(No response) 
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Summary and Conclusion 
 Risk management activities are employed by medical device companies to ensure 
that the intended use and purpose of the medical device are properly addressed and the 
known and foreseeable hazards are well identified. Regardless of the medical device 
classification, the use of the appropriate RM activities according to device type and 
maturity play a significant role in determining the effectiveness of the activities utilized.  
This risk management survey was conducted to understand the use and effectiveness of 
the risk management activities and how these activities impact the medical device 
development.   
 The 14 respondents may not be enough to arrive at a statistically significant 
evaluation of RM activities.  However, a trend is evident in the survey showing a switch 
of the effectiveness ratings in the entire life cycle, and how the degree of change was 
measured throughout the device phase.  Therefore, these results may be used as a guide to 
improve risk management practices. 
 A survey on the implementation and effectiveness of risk management activities 
was carried out in this research to achieve an accurate assessment of how RM activities 
can contribute to the level of change in the design and manufacturing processes and how 
RM activities are recognized as vital to the medical device design and manufacturing 
operations.  
 The degree of change and measure of effectiveness of RM activities based on 
survey results were significantly impacted by the following factors: device type, time 
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since market release, and device development history.  Table 4 summarizes the RM 
effectiveness based on survey results.   
 Further studies on the impact of RM activities in the medical device industry is 
highly encouraged to achieve a better understanding of the significance that these 
activities bring to influence the development of a medical device.   
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Table 4: Summary of RM Effectiveness from the Survey 
Device Type (Number of 
respondent) 
Pre-Market Effectiveness of RM Activities Post-Market Effectiveness of RM Activities 
Surgical Tools & 
catheters (4) 
Relatively more effective for all purposes 
especially second generation devices 
Some effectiveness especially for costs savings 
and product improvement 
Diagnostic devices (3) Relatively more effective for early 
identification and overall design quality 
Relatively less effective (except for catching 
problems and cost savings where RM has some 
effectiveness) 
Implantables (5) Generally rated less effective than for other 
device types. Most effectiveness was 
indicated for overall product quality 
(Not enough respondents had devices in post-
market stage) 
 
Other therapeutic 
devices (1) 
Rated highly effective on all factors (No data) 
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Appendix B: “Scope of File Review by Submission Type” (WHO, 2003) 
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Appendix C: Typical PHA worksheet (ISO, 2007) 
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Appendix F1: Chart for the count and degree of change of the risk management activities performed in the 
conceptualization phase of a medical device 
94 
 
Appendix F2: Chart for the count and degree of change of the risk management activities performed in the initial 
development phase of a medical device 
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Appendix F3: Chart for the count and degree of change of the risk management activities performed in the design 
verification and engineering validation phase of a medical device 
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Appendix F4: Chart for the count and degree of change of the risk management activities performed in the design 
transfer phase of a medical device 
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Appendix F5: Chart for the count and degree of change of the risk management activities performed in the clinical 
validation phase of a medical device 
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Appendix F6: Chart for the count and degree of change of the risk management activities performed in the pilot 
production phase of a medical device 
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Appendix F7: Chart for the count and degree of change of the risk management activities performed in the 
manufacturing scale up phase of a medical device 
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Appendix F8: Chart for the count and degree of change of the risk management activities performed in the production 
monitoring and reporting phase of a medical device 
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Appendix F9: Chart for the count and degree of change of the risk management activities performed in the field 
production monitoring and reporting phase of a medical device 
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Appendix G1: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the conceptualization phase of a medical device 
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Appendix G2: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the initial development phase of a medical device 
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Appendix G3: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the design verification and engineering validation phase of a medical device 
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Appendix G4: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the design transfer phase of a medical device 
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Appendix G5: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the clinical validation phase of a medical device 
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Appendix G6: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the pilot production phase of a medical device 
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Appendix G7: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the manufacturing scale up phase of a medical device 
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Appendix G8: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the production monitoring and reporting phase of a medical device 
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Appendix G9: Chart for the effectiveness and implementation scores of the risk management activities performed in 
the field production monitoring and reporting phase of a medical device 
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Appendix H3: Survey findings 
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Appendix H7: Survey findings
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Appendix H8: Survey findings
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Appendix H10: Survey findings
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Appendix H11: Survey findings 
 
